NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

We not only know that about 66 of 99 SOC patients progressed and crossed over, we also know that many more Treatment patients than SOC patients progressed.

At some point (I don't recall when), Dr. Liau told us that most of the post 36 months survivors arrive at that timeline with their PFS status intact.

I am estimating that at a minimum, 150 of the 233 Treatment patients progressed at some point. They therefore outnumber the 66 control patients who had progressed by more than 2:1.

It is therefore logical that the relatively fewer post 36 months survivors who progressed by the the time they reached that timeline, were treatment patients and still fewer were SOC.

With the exception of few SOC patients who via an imaging error received DCVax-L after their pseudo progression, the SOC patients who really progressed were at a disadvantage when compared to Treatment patients who progressed because they received DCVax-L late whereas the Treatment patients received it early. That most likely has handed the Treatment patients an added longevity advantage.

I therefore expect the 93 post 36 months survivors to follow into the following two groups:

1. Many surviving Treatment patients who did not
progress and very few of the 33 SOC patients who also did not
progress.

2. Few Treatment patients who progressed and even fewer SOC
patients who progressed.

Bottom line: There are many more post 36 months Treatment than Soc
survivors.

.